Our previous work provided an early proof‐of‐concept that the specific pharmacological activation of LRH‐1/NR5A2 using a small chemical agonist (BL001) could therapeutically impede the progression of hyperglycaemia in two mouse models of T1D (NOD and RIP‐B7.1) without long‐term adverse effects, validating the benefits of targeting this NR.19 This evidence concerns the gene NR5A2 and type 1 diabetes mellitus.